Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 2/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28492715 | 0.89 | CD274 (0.35) | DPP4CD274NPC1RAB9A | |
| SCHEMBL28492716 | 0.89 | CD274 (0.35) | DPP4CD274NPC1RAB9A | |
| SCHEMBL26832986 | 0.81 | — | — | |
| SCHEMBL17024347 | 0.81 | — | — | |
| SCHEMBL9733790 | 0.81 | CD274 (0.33) | CD274NPC1RAB9A | |
| SCHEMBL5552483 | 0.80 | DPP7 (0.42) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL28492721 | 0.79 | DPP4 (0.33) | DPP4 | |
| SCHEMBL28492718 | 0.79 | DPP4 (0.33) | DPP4 | |
| SCHEMBL1503225 | 0.78 | CD274 (0.32) | CD274NPC1RAB9A | |
| SCHEMBL1503226 | 0.78 | CD274 (0.32) | CD274NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) | 2007-04-26 | — | — | US | disclosed |
| EP-1513868-B1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL (TR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1513868-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000874-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TI CARET A.S. (TR) | 2003-12-31 | — | — | WO | disclosed |
| US-5359086-A | Process for preparing alkyl-L-alanyl-L-proline derivatives | KRKA, PHARMACEUTICAL & CHEMICAL WORKS (SI) | 1994-10-25 | — | — | US | disclosed |
| US-5359086-A | Process for preparing alkyl-L-alanyl-L-proline derivatives | KRKA, PHARMACEUTICAL & CHEMICAL WORKS (SI) | 1994-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ACE, LOX, AGT | DPP4 78/4885CD274 3565/4885NPC1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.